Financial Advisory Research & Insights
September 15, 2026
Lazard Global Biopharmaceutical Leaders Study 2026
The global biopharmaceutical industry is navigating a reshaped operating environment in 2026.
Lazard Interim 2026 Secondary Market Report
The 2026 secondary market is driven by sponsors turning to continuation funds and trophy-asset exits for liquidity, matched by buyers with strong fundraising, sharper software underwriting, and growing '40 Act and evergreen capital, signaling a durable, structural market shift.
Ron Temple's Global Mid-Year Outlook 2026: Three Core Convictions Shaping Markets
Lazard Chief Market Strategist Ronald Temple explores the forces reshaping global markets in the second half of 2026—including a weakening U.S. dollar, steepening yield curves in developed markets, and a narrowing performance gap between U.S. and non-U.S. markets.
